The largest database of trusted experimental protocols

E coli 055 b5

Manufactured by Merck Group
Sourced in United States

E. coli 055:B5 is a laboratory-used strain of the Escherichia coli bacterium. It is a serotype that is characterized by its O-antigen. This strain is commonly used in research and testing applications.

Automatically generated - may contain errors

47 protocols using e coli 055 b5

1

Rat EGCs and Mouse Macrophages Response to RA and LPS

Check if the same lab product or an alternative is used in the 5 most similar protocols
Rat enteroglial cell line CRL-2690 (EGCs) and mouse macrophage cell line RAW 264.7 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)–high glucose (containing 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin) and maintained at 37 °C in a humidified incubator of 5% CO2.
EGC were seeded in 6-well plates and cultured in the medium containing 0 or 1 nmol/L RA (Sigma-Aldrich, Burlington, MA, USA) and 0 or 1 μg/mL LPS (E. coli 055: B5, Sigma-Aldrich). After 24 h incubation, the supernatants were collected to quantify IL-1β production. The adherent EGCs were harvested for total RNA extraction and total protein extraction.
Rat RAW 264.7 cells were cultured in 6-well plates with medium containing 0 or 1 nmol/L RA (Sigma-Aldrich), 0 or 1 ng/mL GDNF (Sigma-Aldrich), and 0 or 1 μg/mL LPS (E. coli 055: B5, Sigma-Aldrich). After 16 h culture, the supernatants were collected to measure IL-1β and COX-2 production. The adherent macrophages were harvested for total RNA extraction.
+ Open protocol
+ Expand
2

Cytotoxicity Evaluation of Cucumis sativus L. Extract

Check if the same lab product or an alternative is used in the 5 most similar protocols
Since the non-toxicity of the extract is a fundamental pre-requisite, we first tested the cytotoxicity of the CSE in a concentration range of 0.0002–2 mg / ml. No toxicity was showed at any doses tested.
pAECs were seeded in a 96 wells plate (approximately 3 × 103 cells/well) and exposed to increasing doses of Cucumis sativus L. (CSE) (0.02; 0.2; 2 mg/ml) in presence of lipopolysaccharide (LPS) (10 μg/ml) (E. coli 055:B5, Sigma-Aldrich Co, St Louis, MO, USA) for 24 h. Cytotoxicity was evaluated by trypan Blue exclusion dye using Countess® II FL Automated Cell Counter (Life Technologies).
+ Open protocol
+ Expand
3

T cell proliferation assay with neutrophils

Check if the same lab product or an alternative is used in the 5 most similar protocols
Purified T cells were labeled with CFSE (Molecular probes, Life Technologies, Carlsbad, CA, USA) and cultured in 96-well flat bottom plates (Nunclon Delta Surface, Thermo Scientific, Waltham, MA, USA) for 5 days—or otherwise if indicated—at 37°C in IMDM medium (Gibco, Life Technologies, Carlsbad, CA, USA), supplemented with 10% (v/v) fetal calf serum (Bodinco, Alkmaar, The Netherlands), 104 U/mL penicillin, 10 ng/mL streptomycin, 200 mM glutamine, and 0.035% (v/v) β-mercaptoethanol (Sigma-Aldrich, Saint Louis, MO, USA). Proliferation was induced by anti-CD3 (clone 1XE [IgE isotype] hybridoma supernatant, 1:1,000, Sanquin, Amsterdam, The Netherlands) and anti-CD28 (clone 15E8 [IgG1 isotype] at 5 μg/mL, Sanquin) monoclonal antibodies (moAbs; at 20,000 T cells/well). Mature neutrophils from blood or neutrophil progenitors from bone marrow were added in a 1:3 ratio (60,000 neutrophils/well), in the presence or absence of neutrophil-activating stimuli: fMLF (1 μM, Sigma-Aldrich), TNFα (10 ng/mL, Peprotech EC, London, UK) or LPS (20 ng/mL, E. coli 055:B5, Sigma).
After 4–6 days, T cell proliferation, indicated by CFSE dilution, was analyzed by flow cytometry. Cells were harvested from the culture plates and stained with APC-labeled anti-CD4 (clone SK3, BD Biosciences, San Jose, CA, USA) and PerCPCy5.5-labeled anti-CD8 (clone SK1, Biolegend, San Diego, CA, USA) antibodies.
+ Open protocol
+ Expand
4

Endometritis Model in WT and Trem-1 Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
In the experiments, all mice were determined to be in dioestrus. The LPS derived from the E. coli 055:B5 (Sigma‐Aldrich, St. Louis, MO, USA) was used to establish the endometritis model which was performed in accordance with the previous reports (Lv, et al., 2015; Wang, et al., 2019). Briefly, four groups of animals were constituted for establishing the endometritis model: (i) WT mice were given 20 μl PBS by uterine perfusion (n = 7). (ii) Trem‐1−/− mice were given 20 μl PBS by uterine perfusion (n = 5). (iii) WT mice were given 20 μl LPS (2.5 mg ml−1) by uterine perfusion (n = 7). (IV) Trem‐1−/− mice were given 20 μl LPS (2.5 mg ml−1) by uterine perfusion (n = 5). The first two groups receiving PBS treatment were used as controls for the WT or Trem‐1−/− mice receiving LPS management respectively. After 24 h, the blood and the middle part of the uterine horn of each mouse were collected after the experiments.
+ Open protocol
+ Expand
5

Murine Model of Intrauterine Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
These studies utilize a well-established mouse model of intrauterine inflammation created by our lab and resulting in fetal and postnatal brain injury (16 (link), 17 (link)). For these experiments, timed-pregnant CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA) and arrived at our animal facility at embryonic day 11 (E11). On E15, pregnant mice underwent a mini-laparotomy, while under isoflurane anesthesia. Each mouse received an injection into their right uterine horn, between the first and second amniotic sacs proximal to the cervix, as previously described (21 (link)–23 (link)). Each injection was either 100µl sterile phosphate buffered saline (PBS; saline control group) or 50µg/100µl lipopolysaccharide (LPS)/sterile PBS (IUI-exposed group). LPS was from E. coli 055:B5 (Sigma, St. Louis, MO). Mice were then euthanized by CO2 either 48 or 72 hours post-IUI, with tissues collected only from mice that were still pregnant. All animal care and use procedures are approved by the University of Pennsylvania IACUC.
+ Open protocol
+ Expand
6

Microglia Proliferation Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Microglia proliferation was measured by the detection of 5-bromo-20-deoxyuridine (BrdU) (Roche diagnostics GmbH) incorporation into the DNA. Microglia were treated with increasing concentrations of ganciclovir (0.05–1 mM) in the presence or absence of LPS (100 ng/ml; E. coli 055:B5; Sigma-Aldrich) and incubated for 48 h. BrdU (10 μM) was added to the medium for the last 24 h. Cells were fixed with 4% paraformaldehyde and stainings for microglia (Iba1, Wako) and BrdU were performed as previously described30 (link). Labelled cells were analysed using a fluorescent microscope and proliferation index was calculated by dividing number of BrdU-positive cells with total number of Iba1 positive cells.
+ Open protocol
+ Expand
7

Antenatal LPS Exposure and Caffeine Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
Experiments were performed on timed-pregnancy Sprague Dawley rats (Charles River
Laboratories, Portage, MI). All experimental procedures were conducted in accordance with
NIH guidelines and institutional approval. Maternal animals were anesthetized, and after
exposing the rat uterus by laparotomy, LPS (E. coli 055:B5, Sigma) or NS
control solution was injected into each amniotic sac (1 μg/amniotic sac) on day 20
in a volume of 10 μl. After returning the uterus to the abdomen, animals recovered
in individual cages under close observation. Pups were delivered spontaneously two days
after LPS or NS injections. A total of 3-4 dams were employed per study protocol, and
survival of pups was 75-90%, which did not differ between antenatal LPS or NS exposure.
Caffeine base (10 mg/kg/d), or water placebo, was given orally for 14 days starting from
postnatal day one (p1) to subgroups of pups exposed to LPS or NS (Figure 1). Caffeine blood levels were obtained via cardiac puncture and
evaluated by high-performance liquid chromatography at p2, p7 and p14 in an additional 4-5
pups at each age.
+ Open protocol
+ Expand
8

LPS-Induced Hypothermia in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Three-month-old female C57BL/6J mice, and female iNOS-null mice were given intraperitoneally (i.p.) a dose (4 mg/kg body weight) of LPS (E. Coli 055:B5, Sigma, St. Louis), or saline as a control [18 (link), 24 (link)]. Half of each of the LPS-treated and control mice received i.p. a single injection (40 mg/kg body weight) of LA 30 min before or after the LPS injection [18 (link)]. To help distinguish the effect of LA on hypothermia from other antioxidants, four LPS-treated mice were i.p. injected with ascorbate (pH 7.0 previously adjusted with NaOH; 5 mg/g of body weight) [25 (link)]. The dosage of LA was based on our experience and that of other investigators [26 (link)-29 (link)]. Body temperature was monitored for 4 hours after LPS injection using rectal temperature sensors (Physitemp Instruments Inc. Clifton, NJ). The experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of North Carolina and complied with the U. S. National Institutes of Health standards.
+ Open protocol
+ Expand
9

LPS-Induced Tolerance in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice at the age of 9–10 weeks were intraperitoneally injected with saline or LPS from E. coli 0111:B4 or E. coli 055:B5 (Sigma-Aldrich) at the indicated dose once a day. To study the tolerance of LPS, mice at the age of 9–10 weeks were intraperitoneally injected with LPS from E. coli 0111:B4 at a dose of 0.8 mg/kg body weight once a day or without injection for one week. After 0, 1, 2, 3 or 4 weeks, the mice were injected with LPS at a dose of 0.8 mg/kg body weight once a day for one or three days.
+ Open protocol
+ Expand
10

Continuous LPS Delivery in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
LPS was administered subcutaneously via Alzet osmotic pumps (Durect, Cupertino, CA, USA) following the experimental design previously described. Various pump models were used, depending on the duration of the treatment. For 2-week treatments, #1002# osmotic pumps were used, whereas, for 4- and 8-week treatments, the #1004# model was used. Pumps were filled with a solution of LPS (Sigma, from E. coli 055:B5, St Louis, MO, USA) diluted in 0.1 M phosphate-buffered saline. To obtain a continuous LPS delivery of 300 μg kg−1 per day, the LPS concentration was adjusted, depending on the flow specified by the manufacturer.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!